Cyproterone acetate

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 13.09.2021

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Half-lifeThis section has been translated automatically.

48 ± 10 h

IndicationThis section has been translated automatically.

Medium to severe acne, seborrhea, alopecia androgenetica (see alopecia androgenetica in women, alopecia androgenetica in men), hirsutism in women.

Limited indicationThis section has been translated automatically.

6 weeks before planned operations, long-term immobilization (e.g. after accidents), smokers > 30 years, liver diseases (e.g. porphyria), renal failure, heart failure, Z.n. thrombophlebitis, Raynaud's disease, peripheral circulatory disorders, edema.

Dosage and method of useThis section has been translated automatically.

Initially 100 mg/day p.o. from 1st to 10th day of cycle in combination with antiandrogen-estrogen combination preparation (e.g. Diane 35), after clinical improvement 50 mg/day from 1st to 10th day of cycle in combination with Diane 35 or Diane 35 alone.

Notice! In case of absence of menstruation exclude pregnancy before taking again!

Undesirable effectsThis section has been translated automatically.

Anemia, weight gain, gynecomastia, galactorrhea, menstrual disorders, libido loss, cholestasis, liver dysfunction, angioedema, thrombosis, fatigue, depression, muscle weakness, osteoporosis.

InteractionsThis section has been translated automatically.

The blood sugar-lowering effect of insulin, metformin and sulfonylureas is reduced.

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, liver diseases, Z.n. pemphigoid gestationis, liver tumours, consuming diseases (except Prostata-Ca), tendency to thrombosis, sickle cell anaemia, severe diabetes mellitus, severe chronic depression, adolescents before the end of puberty.

PreparationsThis section has been translated automatically.

Androcur®, Virilit®

Authors

Last updated on: 13.09.2021